Orthocell (ASX:OCC) received regulatory clearance from the US Food and Drug Administration for its nerve repair product, Remplir, under the 510(k) pathway, allowing sales in the US market, according to a Friday filing with the Australian bourse.
Products delivered to the US will be manufactured at the company's Western Australia facility, the filing said.
Remplir is approved for sale in Australia, New Zealand, and Singapore, with pending approvals in Canada and Thailand in the next six months, according to the filing.
Shares were down 4% in morning trade Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。